alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Exhibit 32


Certification of Periodic Financial Report
 Pursuant to 18 U.S.C. Section 1350
 
 
 Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, each of the undersigned officers of AMCOL International Corporation (the “Company”) certifies that the quarterly report on Form 10-Q of the Company for the three months ended March 31, 2010 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and information contained in that Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
 
 Date:  April 28, 2010
/s/ Lawrence E. WashowLawrence E. WashowChief Executive OfficerDate:  April 28, 2010
/s/ Donald W. PearsonDonald W. PearsonChief Financial Officer
§ 20.120 Records available in Food and Drug Administration Public Reading Rooms. ( a ) The Freedom of Information Staff and the Dockets Management Staff Public Reading Room are located at the same address. Both are located in Rm. 1061, 5630 Fishers Lane, Rockville, MD 20852. The telephone number for the Docket Management Staff is 240-402-7500; the telephone number for the Freedom of Information Staff's Public Reading Room is located at the address on the Agency's website at *https://www.fda.gov .* Both public reading rooms are open from 9 a.m. to 4 p.m., Monday through Friday, excluding legal public holidays.
( b ) The following records are available at the Division of Freedom of Information Public Reading Room: ( 1 ) A guide for making requests for records or information from the Food and Drug Administration;
( 2 ) Administrative staff manuals and instructions to staff that affect a member of the public;
( 3 ) Food and Drug Administration records which have been released to any person in response to a Freedom of Information request and which the agency has determined have become or are likely to become the subject of subsequent requests for substantially the same records;
( 4 ) Indexes of records maintained in the Division of Freedom of Information Public Reading Room; and
( 5 ) Such other records and information as the agency determines are appropriate for inclusion in the public reading room.
( c ) The following records are available in the Dockets Management Staff's Public Reading Room: ( 1 ) Final opinions, including concurring and dissenting opinions, as well as orders, made in the adjudication of cases;
( 2 ) Statements of policy and interpretation adopted by the agency that are still in force and not published in the Federal Register;
( 3 ) Indexes of records maintained in the Dockets Management Staff's Public Reading Room; and
( 4 ) Such other records and information as the agency determines are appropriate for inclusion in the public reading room.
( d ) The agency will make reading room records created by the Food and Drug Administration on or after November 1, 1996, available electronically through the Internet at the agency's World Wide Web site which can be found at *http://www.fda.gov .* At the agency's discretion, the Food and Drug Administration may also make available through the Internet such additional records and information it believes will be useful to the public.
[68 FR 25287, May 12, 2003; 68 FR 65392, Nov. 20, 2003, as amended at 76 FR 31470, June 1, 2011; 79 FR 68115, Nov. 14, 2014; 87 FR 55914, Sept. 13, 2022; 88 FR 45065, July 14, 2023]
Fortissimo
      Capital Fund GP, L.P.

    14
      Hamelacha Street 

    Park
      Afek, Rosh Ha’ayin 48091 Israel 

    


    


    AGREEMENT
      TO FUND DISSOLUTION EXPENSES

    


    


    August
      7,
      2006

    


    


    To
      the
      Board of Directors of

    Fortissimo
      Acquisition Corp.

    


    Gentlemen:

    


    The
      undersigned, Fortissimo Capital Fund GP, L.P., hereby agrees as follows with
      respect to the dissolution and liquidation of Fortissimo Acquisition Corp.
      (the
“Corporation”) in the event that the Corporation does not complete a business
      combination within 18 months after the consummation of the Corporation’s initial
      public offering of securities (“IPO”) (or within 24 months after the
      consummation of the IPO if a letter of intent, agreement in principle or
      definitive agreement has been executed within 18 months after consummation
      of
      the IPO and the business combination has not yet been consummated within such
      18
      month period).

    


    In
      the
      event that the Corporation’s remaining net assets following the distribution of
      the trust account to its public stockholders (whether they purchased shares
      in
      the IPO or in the aftermarket) are insufficient to pay for the costs associated
      with the implementation and completion of the Corporation’s plan of dissolution
      , FCF will advance to the Corporation the funds necessary to complete such
      dissolution (currently anticipated to be no more than approximately $50,000)
      and
      has agreed not to seek repayment for such expenses.

    


     

    [REMAINDER
      OF PAGE INTENTIONALLY BLANK. SIGNATURE PAGE FOLLOWS]

     

    


    



    


    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    
      To
        the
        Board of Directors of

      Fortissimo
        Acquisition Corp.

      August
        7,
        2006

      Page
        2

      


      




    Very
      truly yours,

    


    FORTISSIMO
      CAPITAL FUND GP, L.P.

    


    


    By:
      /s/
      Yuval
      Cohen               
  

    Name:
      Yuval Cohen

    Title:
      Managing Partner

    


    


    


    Agreed
      To
      and Accepted By:

    


    FORTISSIMO
      ACQUISITION CORP.

    


    


    By:
      /s/
      Yuval
      Cohen                  

    Name:
      Yuval Cohen

    Title:
      Chairman of the Board and Chief
      Executive Officer
* Pursuant to Local Rule 47.5, the court has determined

that this opinion should not be published and is not precedent except under the limited circumstances set forth in Local Rule 47.5.4. IN THE UNITED STATES COURT OF APPEALS FOR THE FIFTH CIRCUIT

No. 96-30578 Summary Calendar

UNITED STATES OF AMERICA, Plaintiff-Appellee,

versus ZAIRE HUMPHREY, Defendant-Appellant.

- - - - - - - - - - Appeal from the United States District Court for the Eastern District of Louisiana

USDC No. 95-CR-315-E

- - - - - - - - - - November 25, 1996 Before JONES, DeMOSS and PARKER, Circuit Judges. PER CURIAM: * Zaire Humphrey appeals from his conviction for distribution of cocaine, in violation of 21 U.S.C. § 841(a)(1). Our review of the record and the arguments and authorities convince us that no reversible error was committed. Humphrey’s entrapment claim is without merit because a reasonable jury could find, beyond a reasonable doubt, that he was disposed to commit the criminal act prior to first being approached by Government agents. See UnitedNo. 96-30578 - 2 - States v. Sandoval , 20 F.3d 134, 137 (5th Cir. 1994). Nor has Humphrey shown that his Sixth Amendment right to confront the Government’s witnesses was violated. See United States v. Pace , 10 F.3d 1106, 1113 (5th Cir. 1993), cert. denied , 114 S. Ct. 2180 (1994). AFFIRMED.
Order entered October 17, 2018

In The 

## Court of Appeals Fifth District of Texas at Dallas

No. 05
- 18
- 00176
- CR
RAYMOND ELLIS NEWSOM E, Appellant

V. THE STATE OF TEXAS, Appellee On Appeal from the 36 3rd Judicial District Court

Dallas County, Texas Trial Court Cause No. F14
- 20384
- W



### O RDER Before the Court is appellant’s October 16, 2018 motion to supplement the record.
A ppellant asserts that, after the jury retired to de termine punishment, appellant made an objection on the record in which he reference d a pretrial hearing on extraneous crimes, wrongs or other acts. Appellant notes that the reporter’s record on file in this Court does not contain any pretrial hearing s and asks that the record be suppl emented to include the pretrial hearing. After reviewing the reporter’s record, we confirm there is no pretrial hearing contained in the record.
We have also reviewed the trial court’s docket sheet and note there is no reference to a pretrial hearing in the docket sheet

. We GRANT appellant’s motion to the extent that we ORDER official court reporter Patricia Holt and deputy court reporter Darline King LaBar each to file, WITHIN TEN DAYSOF THE DATE OF THIS ORDER , (1) any and all pretrial hearings reported in the above case

or (2) in the event no pretrial hearings were reported, written verification that no pretrial hearings were reported.

/s/ LANA MYERS JUSTICE
#### Potter Real Estate Co., Inc., Appellant, v. O & S Bearing & Mfg. Co., Respondent.

No. 2.

Order insofar as it directs defendant to answer interrogatories within 30 days unanimously affirmed; appeal from remainder of order dismissed as academic, without costs. (Appeal from order of Onondaga Special Term denying motion to strike interrogatories.) Present — Goldman, P. J., Marsh, Witmer, Moule and Bastow, JJ.
EXHIBIT 21.1



SUBSIDIARIES AS OF DECEMBER 31, 2003



|                       |  |                               |  |                   |  
|---------------------- |  | ----------------------------- |  | ----------------- | -
|Name                   |  | Jurisdiction of Incorporation |  | Percent Ownership |  
|GolfWeb                |  | California                    |  | 100               | %
|Sports.com Limited     |  | United Kingdom                |  | 38                | %
|Commissioner.com, Inc. |  | New York                      |  | 100               | %
|MVP.com Sports, Inc.   |  | Delaware                      |  | 100               | %
|SBX Acquisition Corp.  |  | Delaware                      |  | 100               | %
<PAGE>   1
                                                                   EXHIBIT 23(B)

INDEPENDENT AUDITORS' CONSENT

We consent to the incorporation by reference in this Prospectus Supplement
dated January 22, 1999 to the Registration Statement of Aristar, Inc. on Form 
S-3, as supplemented by the Prospectus dated June 23, 1997, of our report dated 
January 20, 1998, appearing in the Annual Report on Form 10-K of Aristar, Inc. 
for the year ended December 31, 1997 and to the reference to us under the 
heading "Experts" in the Prospectus Supplement, which is part of the 
Registration Statement.

/s/ DELOITTE & TOUCHE LLP

January 22, 1999
Tampa, Florida
<PAGE>   1
                                                                     EXHIBIT 2.0

                          [ARTHUR ANDERSEN LETTERHEAD]

Oslo, July 22, 1999

Teekay Shipping Corporation
Fourth Floor
Euro Canadian Centre
Marlborough Street & Navy Lion Road
PO Box SS-6293
Nassau
The Bahamas


Ladies and Gentlemen,

As independent public accountants, we hereby consent to the incorporation in
Teekay Shipping Corporation's Report on Form 6-K dated on July 22, 1999, of our
Auditors' Report dated March 3, 1999 relating to the consolidated balance
sheets of Bona Shipholding Ltd. and subsidiaries as of December 31, 1998, 1997
and 1996 and the related consolidated statements of income, stockholders'
equity and cash flow for the three years in the period ended December 31, 1998.

We also consent to the incorporation by reference therein of such report in
Teekay Shipping Corporation's Registration Statements on Forms F-3
(Registration Statement File No. 33-97746) and S-8 (Registration Statement file
No. 33-98768) filed with the Securities and Exchange Commission on October 4,
1995 and October 27, 1995, respectively.


Very truly yours,
ARTHUR ANDERSEN & CO.


/s/ MORTEN DRAKE
-------------------------------------------
Morten Drake
State Authorised Public Accountant (Norway)
Editorial Note on Part 201
Editorial Note: Nomenclature changes to part 201 appear at 69 FR 13717, Mar. 24, 2004.

§ 201.22 Prescription drugs containing sulfites; required warning statements. ( a ) Sulfites are chemical substances that are added to certain drug products to inhibit the oxidation of the active drug ingredient. Oxidation of the active drug ingredient may result in instability and a loss of potency of the drug product. Examples of specific sulfites used to inhibit this oxidation process include sodium bisulfite, sodium metabisulfite, sodium sulfite, potassium bisulfite, and potassium metabisulfite. Recent studies have demonstrated that sulfites may cause allergic-type reactions in certain susceptible persons, especially asthmatics. The labeling for any prescription drug product to which sulfites have been added as an inactive ingredient, regardless of the amount added, must bear the warning specified in paragraph (b) or (c) of this section.
( b ) The labeling required by §§ 201.57 and 201.100(d) for prescription drugs for human use containing a sulfite, except epinephrine for injection when intended for use in allergic or other emergency situations, shall bear the warning statement “Contains (*insert the name of the sulfite, e.g., sodium metabisulfite*), a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.” This statement shall appear in the “Warnings” section of the labeling.
( c ) The labeling required by §§ 201.57 and 201.100(d) for sulfite-containing epinephrine for injection for use in allergic emergency situations shall bear the warning statement “Epinephrine is the preferred treatment for serious allergic or other emergency situations even though this product contains (*insert the name of the sulfite, e.g., sodium metabisulfite*), a sulfite that may in other products cause allergic-type reactions including anaphylactic symptoms or life-threatening or less severe asthmatic episodes in certain susceptible persons. The alternatives to using epinephrine in a life-threatening situation may not be satisfactory. The presence of a sulfite(s) in this product should not deter administration of the drug for treatment of serious allergic or other emergency situations.” This statement shall appear in the “Warnings” section of the labeling.
[51 FR 43904, Dec. 5, 1986]
#### In re Bilske

*Charles C. Keller,*for petitioner.

January 8, 1951.

Per Curiam,

Irma Gail Abercrombie, the mother of Albert Bilske, Jr., a minor of the age of four and one-half years, has filed her petition as-his guardian, praying that the name of Albert Bilske, Jr., be changed to Howard Gail Abercrombie. Albert Bilske, the natural father of Albert Bilske, Jr., appears and objects to any change of name. A hearing was held before the court en banc.

We have considered the application and testimony and the objection. After consideration of the remarks by the Supreme Court in Falcucci Name Case, 355 Pa. 588, where the Supreme Court said, “Of course, a court would be reluctant to grant a very youthful minor’s petition for a change of name, but this minor is over 18 years of age,” etc., and further considering the decision of the Court of Common Pleas of Philadelphia County in Rounick’s Petition, 47 D. & C. 71, we have come to the conclusion that the proposed change of name should not receive our approval. We think this action should not be taken until the minor has reached the age where he is capable of determining what name he desires to take.

And now, January 8, 1951, the petition of Irma Gail Abercrombie for a decree to change the name of Albert Bilske, Jr., to Howard Gail Abercrombie is hereby dismissed at the cost of petitioner.
DISTRICT COURT OF APPEAL OF THE STATE OF FLORIDA

FOURTH DISTRICT

GREGORY WASHINGTON,

Appellant,

v.

STATE OF FLORIDA,

Appellee.

No. 4D17-2732

[October 26, 2017]

Appeal of order denying rule 3.800 motion from the Circuit Court for 

the Seventeenth Judicial Circuit, Broward County; Elizabeth Anne 

Scherer, Judge; L.T. Case No. 90-18200CF10A.

Gregory Washington, Okeechobee, pro se.

No appearance required for appellee.

PER CURIAM.

Affirmed.

GROSS, MAY and CONNER, JJ., concur.

* * *

Not final until disposition of timely filed motion for rehearing.
MEMORANDUM 

DATE: November 30, 2009 

TO: The Record 

FROM: Elaine Eby 

SUBJECT: Superfund Cost Estimates for Selected Classes of Facilities 

In October 2009, EPA’s Office of Resource Conservation and Recovery (ORCR) requested from 

the Office of Superfund Remediation and Technology Innovation (OSRTI) information on the 

cost, to date, associated with the clean-up of NPL sites that had been assigned to specific 

NAICS codes, i.e., NAICS 324 – Petroleum and Coal Products Manufacturing and NAICS 325 – 

Chemical Manufacturing. ORCR also requested information on the Chrisman Creek NPL site 

which had been categorized under NAICS 2211 – Electric Power Generation, Transmission and 

Distribution. ORCR provided OSRTI’s Budget, Planning, and Evaluation Branch with a list of 

NPL sites in these categories. (See Email from ChoYi Kwan to Elaine Eby entitled Updated NPL 

Proposed Listing by Year Table, October 8, 2009 which can be found in the docket supporting 

this notice). The following information was provided to ORCR by OSRTI. 

 

For the NPL sites identified in the NAICS 324 category, EPA has spent approximately $250 

million (in 2009 constant dollars) through FY 2009. 

For the NPL sites identified in the NAICS 325 category, EPA has spent approximately $2.7 

billion (in constant 2009 dollars) through FY 2009. 

For the NPL site identified in the NAICS Other category, EPA has spent approximately $1.4 

million (in constant 2009 dollars) through FY 2009. 

These data represent OSRTI’s analysis of end of FY 2009, cumulative, site-specific, agency-wide, 

direct expenditures of Superfund appropriated and reimbursable resources extracted from the 

US EPA Integrated Financial Management System (IFMS). 

Expenditure data include all direct site costs, including, but not limited to, site assessment, 

remedial, removal, enforcement, and oversight costs. Data do not include indirect costs, costs 

incurred by private or other parties performing response actions, or future costs to be incurred 

at these sites and may not be used for cost recovery purposes. 

Expenditure data are converted into 2009 constant dollars using GDP deflation factors derived 

from: 

 Table 10.1--GROSS DOMESTIC PRODUCT AND DEFLATORS USED IN THE HISTORICAL 

TABLES: 1940-2009, from the Budget of the U.S., FY 2005 Online via GPO Access.
Exhibit 23.1


               CONSENT OF INDEPENDENT ACCOUNTANTS
                                
                                
We  consent to the incorporation by reference in the Registration
Statement  of Forcenergy Inc on Form S-8, (File No. 33-80919)  of
our  report  dated  February  17,  1997  on  our  audits  of  the
consolidated  financial  statements  of   Forcenergy  Inc  as  of
December  31, 1996 and 1995, and for the years then ended,  which
report is included in this Annual Report on Form 10-K.



COOPERS & LYBRANDS L.L.P.


Miami, Florida
March 25, 1997
Editorial Note on Part 184
Editorial Note: Nomenclature changes to part 184 appear at 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 69 FR 13717, Mar. 24, 2004; 70 FR 40880, July 15, 2005; 70 FR 67651, Nov. 8, 2005; and 81 FR 49897, July 29, 2016.

§ 184.1061 Lactic acid. ( a ) Lactic acid (C3H6O3, CAS Reg. Nos.: dl mixture, 598-82-3; l-isomer, 79-33-4; d-isomer, 10326-41-7), the chemical 2-hydroxypropanoic acid, occurs naturally in several foods. It is produced commercially either by fermentation of carbohydrates such as glucose, sucrose, or lactose, or by a procedure involving formation of lactonitrile from acetaldehyde and hydrogen cyanide and subsequent hydrolysis to lactic acid.
( b ) The ingredient meets the specifications of the Food Chemicals Codex, 3d Ed. (1981), p. 159, which is incorporated by reference. Copies are available from the National Academy Press, 2101 Constitution Avenue, NW., Washington, DC 20418, or available for inspection at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, call 202-741-6030, or go to: *http://www.archives.gov/federal_register/code_of_federal_regulations/ibr_locations.html .*
( c ) In accordance with § 184.1(b)(1), the ingredient is used in food with no limitation other than current good manufacturing practice. The affirmation of this ingredient as generally recognized as safe (GRAS) as a direct human food ingredient is based upon the following current good manufacturing practice conditions of use: ( 1 ) The ingredient is used as an antimicrobial agent as defined in § 170.3(o)(2) of this chapter; a curing and pickling agent as defined in § 170.3(o)(5) of this chapter; a flavor enhancer as defined in § 170.3(o)(11) of this chapter; a flavoring agent and adjuvant as defined in § 170.3(o)(12) of this chapter; a pH control agent as defined in § 170.3(o)(23) of this chapter; and a solvent and vehicle as defined in § 170.3(o)(27) of this chapter.
( 2 ) The ingredient is used in food, except in infant foods and infant formulas, at levels not to exceed current good manufacturing practice.
( d ) Prior sanctions for this ingredient different from the uses established in this section do not exist or have been waived.
[49 FR 35367, Sept. 7, 1984]
### Surface water supply of the United States, 1924, Part III, Ohio River basin

By: Water Resources Division, U.S. Geological Survey

                            https://doi.org/10.3133/wsp583

#### Links

-                                                                                                                             Document:                                                                                                                                                                                                                                                  **Report**                                                                                                     (pdf)                                                                                                                                     
- Download citation as:  RIS                         |                         Dublin                            Core

#### Abstract

Part or all of this report is presented in Portable Document Format                        (PDF). For best results viewing and printing PDF documents, it is recommended that you download                        the documents to your computer and open them with Adobe Reader. PDF documents opened from your                        browser may not display or print as intended. Download the latest version of Adobe Reader, free of charge. More information                        about viewing, downloading, and printing report files can be found at the common download problems FAQ.